



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/676,873	09/30/2003	John Chan	COTH-P01-002 7993		
28120	7590 05/04/2005	EXAMINER		INER	
FISH & NEAVE IP GROUP			DEJONG, ERIC S		
ROPES & GRAY LLP ONE INTERNATIONAL PLACE			ART UNIT	PAPER NUMBER	
BOSTON, MA	BOSTON, MA 02110-2624			1631	
			DATE MAILED: 05/04/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Office Action Comments	10/676,873	CHAN ET AL.			
Office Action Summary	Examiner	Art Unit			
	Eric S. DeJong	1631			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	86(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days fill apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	ely filed  will be considered timely. the mailing date of this communication.  (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on	_•				
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ This	This action is FINAL. 2b)⊠ This action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.			
Disposition of Claims					
4) ⊠ Claim(s) <u>1-69</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1-69</u> are subject to restriction and/or expressions.					
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examine 11.	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign  a) All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the priority application from the International Bureau  * See the attached detailed Office action for a list	s have been received. s have been received in Application ity documents have been receive I (PCT Rule 17.2(a)).	on No d in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date  S. Patent and Trademark Office	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa				

N

Application/Control Number: 10/676,873

Art Unit: 1631

### **DETAILED ACTION**

### Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-56, drawn to a method for engineering a spatially conserved catalytic motif into a recipient polypeptide that binds a target, classified in class 702, subclass 27. If this group is elected then the two Species Elections summarized below for Group I are also required.
- II. Claims 57-69, drawn to an engineered polypeptide or complex into which a catalytic motif has been engineered, classified in class 435, subclass 183.

The inventions are distinct each from the other because of the following reasons:

The inventions of Groups I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)).

In the instant case the engineered polypeptides and polypeptide complexes of Group II contain an engineered catalytic motif that can be identified as spatially conserved. However, this does not restrict the process by which the engineered polypeptides and polypeptide complexes are made to those processes which rely upon

Art Unit: 1631

spatially conserved motifs. As such, it is conceivable that a polypeptide as instantly claimed in Group II can be engineered with respect to other factors not related to structurally conserved motifs, such as purely functional criteria or common single and multiple site mutation methodologies, and still produce by coincidence the same polypeptides that were engineered by the methodologies presented in Group I.

Therefore, the product of an engineered polypeptide or polypeptide complex from Group II can be made by other and materially different processes than those presented in Group I.

Though claims 60-62 depend from claim 56, they are not considered linking claims for the above reasons. Further, these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by their different classification, and the search required for both groups would not be coextensive and therefor present an undue burden if searched together, the restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product

claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

## FIRST SPECIES ELECTION REGARDING GROUP I

This application contains claims directed to the following patentably distinct species of the claimed invention:

Species of recipients as set forth in claims 1, 2, 17, 36, and 56 are distinct and separately published and described in literature thus presenting an undue burden of searched together.

Applicants are to elect one of the following species of recipients: (A) a recipient that is a polypeptide or (B) a recipient that is a polypeptide complex.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 56 is generic.

If applicants elect above Specie (A), then the following sub-specie elections is also required.

Species of recipient polypeptides as set forth in claims 1, 2, and 17 are distinct and separately published and described in literature thus presenting an undue burden of search if searched together.

Applicants are to elect on of the following species of polypeptide recipients: (C) a recipient polypeptide that binds an extracellular signaling molecule, (D) a recipient polypeptide that catalytically modifies a target, (E) a recipient polypeptide that binds to a receptor for an extracellular signaling molecule, or (F) an unspecified recipient polypeptide with respect to those listed above.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 21, 22, 25-35 are generic.

### SECOND SPECIES ELECTION FOR GROUP I

This application contains claims directed to the following patentably distinct species of the claimed invention:

Species of identifying a set of amino acid residues in a recipient polypeptide as set forth in claims 1, 2, 15, 17, 21, 54, and 56 are distinct and separately published and described in literature thus presenting an undue burden of searched together.

Applicants are to elect one of the following species of identifying a set of amino acid residues: (G) a method that does not include modeling the presence of a  $\beta$ -carbon on a glycine residue of the recipient polypeptide or (H) a method that includes the presence of a  $\beta$ -carbon on a glycine residue of the recipient polypeptide.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim no claim is generic.

Application/Control Number: 10/676,873

Art Unit: 1631

Applicant is advised that the reply to the above requirements must include an identification of the species that are elected consonant with these requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eric S. DeJong whose telephone number is (571) 272-6099. The examiner can normally be reached on 8:30AM-5:00PM.

Art Unit: 1631

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, Ph.D. can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is (571) 272-8300.

Any inquiry of a general nature or relating to the status of this application should be directed to Legal Instrument Examiner, Tina Plunkett, whose telephone number is (571) 272-0549.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

EDJ CN1

ARDIN H. MARSCHEL 4/30/05